The RIGL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RIGL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The RIGL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View RIGL Detailed Price Forecast - CNN Money||View RIGL Detailed Summary - Google Finance|
|View RIGL Detailed Summary - Yahoo! Finance||View RIGL Stock Research & Analysis - Zacks.com|
|View RIGL Trends & Analysis - Trade-Ideas||View RIGL Major Holders - Barrons|
|View RIGL Call Transcripts - NASDAQ||View RIGL Breaking News & Analysis - Seeking Alpha|
|View RIGL Annual Report - CompanySpotlight.com||View RIGL OTC Short Report - OTCShortReport.com|
|View RIGL Fundamentals - TradeKing||View RIGL SEC Filings - Bar Chart|
|View Historical Prices for RIGL - The WSJ||View Performance/Total Return for RIGL - Morningstar|
|View the Analyst Estimates for RIGL - MarketWatch||View the Earnings History for RIGL - CNBC|
|View the RIGL Earnings - StockMarketWatch||View RIGL Buy or Sell Recommendations - MacroAxis|
|View the RIGL Bullish Patterns - American Bulls||View RIGL Short Pain Metrics - ShortPainBot.com|
|View RIGL Stock Mentions - StockTwits||View RIGL Stock Mentions - PennyStockTweets|
|View RIGL Stock Mentions - Twitter||View RIGL Investment Forum News - Investor Hub|
|View RIGL Stock Mentions - Yahoo! Message Board||View RIGL Stock Mentions - Seeking Alpha|
|View Insider Transactions for RIGL - SECform4.com||View Insider Transactions for RIGL - Insider Cow|
|View RIGL Major Holdings Summary - CNBC||View Insider Disclosure for RIGL - OTC Markets|
|View Insider Transactions for RIGL - Yahoo! Finance||View Institutional Holdings for RIGL - NASDAQ|
|View RIGL Stock Insight & Charts - FinViz.com||View RIGL Investment Charts - StockCharts.com|
|View RIGL Stock Overview & Charts - BarChart||View RIGL User Generated Charts - Trading View|
New Research: Key Drivers of Growth for SpartanNash, Nustar GP, Hornbeck Offshore Services, TiVo, Eli Lilly, and Rigel Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
Posted on Wednesday February 21, 2018
NEW YORK, Feb. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SpartanNash ...
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Posted on Friday February 16, 2018
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2018 /PRNewswire/ -- Rigel Pharmaceuticals (RIGL) today announced that on January 24, 2018 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 30,000 shares of common stock to one new employee. This award was granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, as an inducement material to the new employee entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Rigel granted stock options to purchase shares of Rigel's common stock to the employee with an exercise price of $3.79 per share, the closing price of Rigel's common stock on February 9, 2018, the first trading date prior to February 12, 2018, the effective date of such grant.
3 Small-Cap Biotech Stocks With Major Catalysts in 2018
Posted on Saturday January 06, 2018
Good news this year could make these small biotech stocks bigger.
Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
Posted on Thursday January 04, 2018
SOUTH SAN FRANCISCO, Calif., Jan. 4, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present an update on its product pipeline and a financial overview at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 10, 2018, at 1:30pm PST (see webcast details below). Rigel's presentation will include a review of the company's New Drug Application (NDA) for fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in adult patients with immune thrombocytopenia (ITP). The FDA has confirmed that it does not plan to convene an Oncology Drugs Advisory Committee (ODAC) meeting to discuss the NDA. The action date for the FDA to complete its review is April 17, 2018 under the Prescription Drug User Fee Act (PDUFA).